SEC 13F Intelligence

Avidity Partners Management LP / ARWR

Avidity Partners Management LP’s Arrowhead Pharmaceuticals In Position

Does Avidity Partners Management LP own Arrowhead Pharmaceuticals In (ARWR)? Not currently — the last reported position was 714.0K shares worth $22M in Q4 2023; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$22M
Q4 2023
Shares
714.0K
% of Portfolio
+0.80%
Quarters Held
11
position exited

Position History ARWR

Reported value by quarter
Q2 ’21: $9MQ2 ’21Q3 ’21: $42MQ4 ’21: $58MQ4 ’21Q1 ’22: $44MQ2 ’22: $51MQ2 ’22Q3 ’22: $41MQ4 ’22: $56MQ4 ’22Q1 ’23: $44MQ2 ’23: $33MQ2 ’23Q3 ’23: $29MQ4 ’23: $22MQ4 ’23filingsflow.com
QuarterSharesValue% of Portfolio
Q4 2023714.0K$22M+0.80%
Q3 20231.06M$29M+1.15%
Q2 2023925.0K$33M+1.15%
Q1 20231.74M$44M+1.47%
Q4 20221.38M$56M+1.21%
Q3 20221.26M$41M+0.84%
Q2 20221.44M$51M+1.16%
Q1 2022955.0K$44M+0.91%
Q4 2021875.0K$58M+1.23%
Q3 2021673.7K$42M+0.93%
Q2 2021104.0K$9M+0.23%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Avidity Partners Management LP’s full portfolio or all institutional holders of ARWR.